A Phase 2 interventional study of GenSci120 150 mg and GenSci120 600 mg in Rheumatoid Arthritis, sponsored by Changchun GeneScience Pharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-05-22.
Sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 249 studies in Arthritis, Rheumatoid with a site in China — 63 open to participants now, 72 under way, 3 of them phase 3. Arthritis, Rheumatoid · China.
Among the 249 studies in Arthritis, Rheumatoid with a site in China, this one is the 37th largest by planned enrollment of the 217 interventional ones that give a count, is one of 19 that started in 2026, is one of 34 in phase 2, reaches primary completion later than 47 of the 71 other live ones, and was the 234th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →63 of the 249 studies in Arthritis, Rheumatoid with a site in China are open now. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in China, United States, Belgium and 8 more countries
Ages 18–65
Peking University People's Hospital · Sites in China
Ages 18+
Jacobio Pharmaceuticals Co., Ltd. · Sites in China
Ages 18–75
Peking Union Medical College Hospital · Sites in China
Ages 18–65
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18–70
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
249 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 58 · Phase 2 46 · Phase 3 52 · Phase 4 28
First in 2003; this study’s year is marked. 19 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 450 is above the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 134 across the 217 interventional studies, 287 across the 32 observational. Of the 115 that completed or were terminated, 28 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
129 of 249 have an industry lead sponsor. The 10 most frequent:
Changchun GeneScience Pharmaceutical Co., Ltd. is the lead sponsor of 112 studies on the registry; 48 are open to participants now.
Changchun GeneScience Pharmaceutical Co., Ltd. has 3 studies filed under Arthritis, Rheumatoid — fewer than ten, so there is no comparison to draw.
16 of the studies in Arthritis, Rheumatoid with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06887127Phase 3Hangzhou Highlightll Pharmaceutical Co., LtdA Long-term Extension Clinical Study of TLL-018 in Patients With Rheumatoid Arthritis | 2026-12-31 |
| NCT07408024Toll Biotech Co. Ltd. (Beijing)Safety and Efficacy of TollB-001 Tablets in Moderate to Severe Rheumatoid Arthritis | 2026-12 |
| NCT07045896Peking University People's HospitalFucoidan in the Treatment of Active Rheumatoid Arthritis | 2026-12 |
| NCT06945666Jie ChangA Study of Iguratimod in Combination With Tofacitinib in RA Patients | 2027-01-31 |
| NCT07491016Zhejiang Provincial People's HospitalEfficacy and Safety of Telitacicept Combined With Baricitinib for Refractory Rheumatoid Arthritis | 2027-03-30 |
Add all 16 to your calendar (.ics) → With an account.
Among the 249 studies in Arthritis, Rheumatoid with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multicenter, randomized, double-blind, parallel, placebo- and active comparator- controlled clinical study conducted in patients with moderately to severely active RA and an inadequate response to at least one DMARD, designed to assess the efficacy and safety of GenSci120 injection in this patient population. The study consists of a screening period (≤ 4 weeks), a placebo-controlled treatment period (14 weeks), an extension treatment period (14 weeks), and a follow-up period (10 weeks), with a total of 17 scheduled visits.
This is a multicenter, randomized, double-blind, parallel, placebo- and active comparator- controlled clinical study conducted in patients with moderately to severely active RA and an inadequate response to at least one DMARD, designed to assess the efficacy and safety of GenSci120 injection in this patient population. The study consists of a screening period (≤ 4 weeks), a placebo-controlled treatment period (14 weeks), an extension treatment period (14 weeks), and a follow-up period (10 weeks), with a total of 17 scheduled visits.
Participants who meet the inclusion criteria will be randomized in a 1:1:1:1:1 ratio to the GenSci120 low dose group-150 mg (Group A), GenSci120 medium dose group-600 mg (Group B), GenSci120 high dose group-1000 mg (Group C), adalimumab group (Group D), and placebo group (Group E), with 90 participants in each group, totaling 450 participants. Among them, the proportion of participants who "have treatment experience of at least one bDMARDs or tsDMARDs" is at least 40%.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Starting from Day 1 (Week 0), GenSci120 150 mg once every 4 weeks (Q4W) until Week 24 (3 injection points are complemented by GenSci120 simulant to maintain blindness). Starting from Week 2, adalimumab simulant until Week 26
Drug: GenSci120 150 mg
Starting from Day 1 (Week 0), GenSci120 600 mg Q4W until Week 24 (3 injection points are complemented by GenSci120 simulant to maintain blindness). Starting from Week 2, adalimumab simulant until Week 26
Drug: GenSci120 600 mg
Starting from Day 1 (Week 0), GenSci120 1000 mg Q4W until Week 24. Starting from Week 2, adalimumab simulant until Week 26
Drug: GenSci120 1000 mg
Starting from Day 1 (Week 0), adalimumab injection 40 mg Q2W until Week 26 (3 injection points are complemented by GenSci120 simulant at Weeks 0, 4, 8, 12, 16, 20, and 24 to maintain blindness)
Drug: adalimumab injection 40 mg
Placebo-controlled treatment period: Starting from Day 1 (Week 0), GenSci120 simulant (3 injection points) Q4W until Week 12, and starting from Week 2, adalimumab simulant until Week 14. Extension treatment period: Starting from Week 16, all participants in the placebo group will receive GenSci120 600 mg Q4W until Week 24, and starting from Week 18, they will receive adalimumab simulant until Week 26
Drug: GenSci120 600 mg · Drug: Placebo
subcutaneous injection
subcutaneous injection
subcutaneous injection
subcutaneous injection
subcutaneous injection
Proportion of participants achieving the American College of Rheumatology 20% improvement criteria (ACR20) for disease activity assessment in RA from baseline after 14 weeks of administration
Time frame: from baseline after 14 weeks of administration
Proportion of participants who meet the improvement criteria for ACR20, ACR50, and ACR70 at each visit (excluding the primary endpoint) after baseline
Time frame: at Week 2,4,6,8,10,12,14,16,18,20,22,24,26,28,38
Changes from baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (DAS28-CRP) at each post-baseline visit.
Time frame: at Week 2,4,6,8,10,12,14,16,18,20,22,24,26,28,38
Changes from baseline in DAS28-erythrocyte sedimentation rate (ESR) at each post-baseline visit
Time frame: at Week 2,4,6,8,10,12,14,16,18,20,22,24,26,28,38
Changes from baseline in Clinical Disease Activity Index (CDAI) at each post-baseline visit
Time frame: at Week 2,4,6,8,10,12,14,16,18,20,22,24,26,28,38
Changes from baseline in Simplified Disease Activity Index (SDAI) scores at each post-baseline visit
Time frame: at Week 2,4,6,8,10,12,14,16,18,20,22,24,26,28,38
Changes from baseline in hsCRP levels/ESR at each post-baseline visit
Time frame: at Week 2,4,6,8,10,12,14,16,18,20,22,24,26,28,38
Proportion of participants achieving DAS28-CRP ≤ 3.2/ DAS28-ESR≤3.2/ CDAI≤10/ SDAI≤11/ DAS28-CRP<2.6/ DAS28-ESR<2.6/ CDAI≤2.8/ SDAI≤3.3/ who meet the Boolean remission criteria at baseline and each subsequent visit
Time frame: at Week 2,4,6,8,10,12,14,16,18,20,22,24,26,28,38
Changes from baseline in SJC/TJC/HAQ-DI at each post-baseline visit
Time frame: at Week 2,4,6,8,10,12,14,16,18,20,22,24,26,28,38
Changes from baseline in Patient global assessment of disease activity(PGA)at each post-baseline visit
Time frame: at Week 2,4,6,8,10,12,14,16,18,20,22,24,26,28,38
Changes from baseline in Evaluator global assessment of disease activity(EGA)at each post-baseline visit
Time frame: at Week 2,4,6,8,10,12,14,16,18,20,22,24,26,28,38
Changes from baseline in Patient's assessment of pain(VAS)at each post-baseline visit
Time frame: at Week 2,4,6,8,10,12,14,16,18,20,22,24,26,28,38
Proportion of participants with Health Assessment Questionnaire-Disability Index(HAQ-DI)improvement (decrease from baseline of at least 0.22) (at Week 12, 14, 24, 28, and 38)
Time frame: at Week 12, 14, 24, 28, and 38
Changes from baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Scale (at Week 12, 14, 24, 28, and 38)
Time frame: at Week 12, 14, 24, 28, and 38
Changes from baseline in severity and duration of morning stiffness at baseline and subsequent visits
Time frame: at Week 2,4,6,8,10,12,14,16,18,20,22,24,26,28,38
Safety measures such as adverse events and serious adverse events
Time frame: at Week 2,4,6,8,10,12,14,16,18,20,22,24,26,28,38
Concentration of GenSci120 in serum samples
Time frame: Baseline, Day 15, Day 29, Day 57, Day 85, Day 99, Day 197, Day 267
Incidence and the time of anti-drug antibody (ADA) positive and neutralizing antibody (NAb) positive (if applicable) after GenSci120 administration
Time frame: Baseline, Day 15, Day 29, Day 57, Day 85, Day 197, Day 267
Total T cell counts detected by flow cytometry, as well as the percentage changes from baseline
Time frame: Baseline, Day 15, Day 29, Day 57, Day 85, Day 197, Day 267
Regulatory T cells (Treg cells) counts detected by flow cytometry, as well as the percentage changes from baseline
Time frame: Baseline, Day 15, Day 29, Day 57, Day 85, Day 197, Day 267
Programmed death receptor-1 (PD-1) expressing total T cell counts detected by flow cytometry, as well as the percentage changes from baseline
Time frame: Baseline, Day 15, Day 29, Day 57, Day 85, Day 197, Day 267
High PD-1 expressing total T cell counts detected by flow cytometry, as well as the percentage changes from baseline
Time frame: Baseline, Day 15, Day 29, Day 57, Day 85, Day 197, Day 267
Follicular helper T cell (Tfh cell) counts detected by flow cytometry, as well as the percentage changes from baseline
Time frame: Baseline, Day 15, Day 29, Day 57, Day 85, Day 197, Day 267
Peripheral helper T cell (Tph cell) counts detected by flow cytometry, as well as the percentage changes from baseline
Time frame: Baseline, Day 15, Day 29, Day 57, Day 85, Day 197, Day 267
Total B cell counts detected by flow cytometry, as well as the percentage changes from baseline
Time frame: Baseline, Day 15, Day 29, Day 57, Day 85, Day 197, Day 267
Plasma cell counts detected by flow cytometry, as well as the percentage changes from baseline
Time frame: Baseline, Day 15, Day 29, Day 57, Day 85, Day 197, Day 267
Serum concentration and the percentage changes from baseline of Interferon-γ (IFN-γ)
Time frame: Baseline, Day 15, Day 29, Day 57, Day 85, Day 197, Day 267
Serum concentration and the percentage changes from baseline of interleukin-6 (IL-6)
Time frame: Baseline, Day 15, Day 29, Day 57, Day 85, Day 197, Day 267
Serum concentration and the percentage changes from baseline of tumor necrosis factor-α (TNF-α)
Time frame: Baseline, Day 15, Day 29, Day 57, Day 85, Day 197, Day 267
Serum concentration and the percentage changes from baseline of chemokine CXC ligand-13 (CXCL-13)
Time frame: Baseline, Day 15, Day 29, Day 57, Day 85, Day 197, Day 267
Serum concentration and the percentage changes from baseline of interleukin-21 (IL-21)
Time frame: Baseline, Day 15, Day 29, Day 57, Day 85, Day 197, Day 267
Serum concentration and the percentage changes from baseline of soluble programmed cell death receptor-1 (sPD-1)
Time frame: Baseline, Day 15, Day 29, Day 57, Day 85, Day 197, Day 267
Serum concentration and the percentage changes from baseline of soluble programmed cell death ligand-1 (sPD-L1)
Time frame: Baseline, Day 15, Day 29, Day 57, Day 85, Day 197, Day 267
Serum concentration and the percentage changes from baseline of soluble programmed cell death ligand-2 (sPD-L2)
Time frame: Baseline, Day 15, Day 29, Day 57, Day 85, Day 197, Day 267
Concentration and the percentage changes from baseline of serum amyloid A (SAA)
Time frame: Baseline, Day 15, Day 29, Day 57, Day 85, Day 197, Day 267
Started Apr 2026 (actual). Primary completion is estimated for Sep 2027, 17 months after the start.
Of 116 industry-sponsored phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's planned 17 months is close to that.
Counting every sponsor, half of 158 studies reached it within 18 months; a quarter within 13 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: GENSCI120
Changchun GeneScience Pharmaceutical Co., Ltd. →